Retrospective study on Attana’s track record published in IBI shows extraordinary results
Today, a retrospective study on Attana’s track record was published in IBI (International Biopharmaceutical Industry). The study evaluates the outcome of all the 77 drug candidates Attana has analyzed for customers in the pre-clinical phase.
The result of the study shows Attana has had an accuracy of 100% in determining which candidates will succeed in clinical trials, outperforming the company’s previously communicated expectations. The findings suggest that Attana’s proprietary technology and validation process has improved clinical trial success rates by over 80%. If the accuracy of the results is scalable throughout the industry, it is facing a major increase in productivity and profitability, with Attana leading the way.
Brief summary of the study:
The challenge in developing new pharmaceutical drugs
The average R&D cost for a pharmaceutical drug is approximately $2 billion, out of which roughly half is related to clinical trials. Today, only 1 out of 10 candidates that enter clinical trials successfully reach the commercial market, primarily as a result of poor testing and analysis in the pre-clinical phase.
A solution for improving the R&D process
With Attana’s proprietary QCM technology and instruments, the company has the ability to analyze how a given pharmaceutical drug will interact with the human body by mirroring in vivo-conditions. By evaluating efficacy and identifying potential side effects with great accuracy, Attana can classify the drug candidates as either promising or unqualified before entering clinical trials.
A proven track record of success
To date, Attana has analyzed 77 candidates of which 30 have been validated and determined to be promising, some after modifications based on Attana’s recommendations. In a short period of time, 8 of the validated candidates have entered clinical trials and 6 out of 6 have successfully completed phase I. InDex Pharmaceutical’s candidate, Cobitolimod, has already reached phase III after being validated by Attana in 2016. Of the 47 candidates classified by Attana as unqualified, none has entered clinical trials to the company’s knowledge.
The track record shows Attana’s accuracy of 100% in classifying candidates prior to clinical trials. Assuming the outcome of Attana’s validated candidates follows industry average transition rates for future phases, Attana has improved the overall clinical trial success rate by more than 80%. By accurately classifying candidates prior to clinical trials, Attana allows pharmaceutical companies to focus on the most promising candidates, increasing their efficiency and profitability.
Read the full study here.
Comment from Teodor Aastrup, CEO of Attana:
“With this retrospective study, we have been able to show that we, already in the pre-clinical phase, can significantly improve the outcome of clinical trials in phase l, ll or lll. If the results of the molecules we have analyzed are scalable on the whole industry, which we believe they are, pharmaceutical companies face a major increase in productivity and profitability with our solution.”
For more information, please contact:
Niklas Carlsson, COO
niklas.carlsson@attana.com
+46 (0)73 867 67 62
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
About Attana
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in-vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.se or contact sales@attana.com.
Tags:
